PharmaTher Holdings Ltd. (PHRRF) Research

PharmaTher Holdings Ltd. is a biotechnology firm in the clinical stage, specializing in psychedelic treatments. Its primary objective is to investigate, develop, and bring to market innovative applications, drug forms, and administration techniques for psychedelics, addressing conditions such as mental health issues, neurological diseases, and chronic pain. Among its pipeline of products, the company is advancing an intravenous ketamine injection, which is currently undergoing Phase II and III clinical trials for its potential use in treating Parkinson's disease, providing anesthesia and sedation, and managing amyotrophic lateral sclerosis (ALS). Additionally, PharmaTher is developing a Ketamine Patch, in Phase I and II trials for conditions like depression, various mental health disorders, complex regional pain syndrome (CRPS), and other pain-related ailments. A Ketamine Pump is also part of their development, currently in Phase II clinical trials for applications in mental health, pain management, and surgical/procedural settings. Furthermore, the company is actively working on PHARMAPATCH, a microneedle patch designed for the transdermal delivery of psychedelic compounds. PharmaTher has established several strategic partnerships to further its development. These include collaborations with LTS Lohmann Therapie-Systeme AG for a ketamine microneedle patch, Alcami Corporation for ketamine injectables and infusions, and BioRAE, Inc. for ketamine pump development. They are also working with Revive Therapeutics Ltd. on a psilocybin microneedle patch and with Gesval S.A. on a patented continuous-flow process for producing ketamine and its analogs. The company is also developing its own proprietary wearable ketamine delivery system, specifically tailored for mental health, neurological, and pain disorders. Established in 2019, the company maintains its headquarters in Toronto, Canada.

Open PharmaTher Holdings Ltd. (PHRRF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.